Last updated: July 31, 2026
Fosinopril sodium/hydrochlorothiazide is a mature, generic fixed-dose antihypertensive combination marketed in the United States under the former brand Monopril HCT. The product combines the ACE inhibitor fosinopril with the thiazide diuretic hydrochlorothiazide. Its clinical development is complete, no meaningful active clinical-trial program is publicly identified, and the product has limited commercial momentum relative to newer antihypertensive combinations.
The principal business risks are generic price compression, declining use of legacy ACE inhibitor combinations, and competition from losartan-, valsartan-, lisinopril-, amlodipine-, and other fixed-dose products. Biosimilar risk is not relevant because the product is a chemically synthesized small molecule.
What is fosinopril sodium/hydrochlorothiazide used for?
Fosinopril sodium/hydrochlorothiazide is indicated for the treatment of hypertension. The combination is intended for patients who require more than one antihypertensive mechanism or who have not achieved adequate blood-pressure control with either component alone.
Fosinopril inhibits angiotensin-converting enzyme, reducing formation of angiotensin II and aldosterone. Hydrochlorothiazide increases sodium and water excretion. The combination can produce greater blood-pressure reduction than either agent used separately.
The product has historically been supplied in fixed-dose tablet strengths combining:
| Fosinopril sodium |
Hydrochlorothiazide |
| 10 mg |
12.5 mg |
| 20 mg |
12.5 mg |
| 20 mg |
25 mg |
Product availability varies by country and manufacturer. The U.S. reference product was Monopril HCT, sponsored by Bristol-Myers Squibb and approved under NDA 020149, according to FDA product records and labeling materials.[1,2]
What are the principal safety risks?
The principal labeled risks are hypotension, impaired renal function, hyperkalemia, cough, angioedema, electrolyte abnormalities, and fetal toxicity. Hydrochlorothiazide can cause hyponatremia, hypokalemia, hyperuricemia, glucose intolerance, and photosensitivity. Fosinopril is contraindicated during pregnancy because renin-angiotensin-system inhibition can cause fetal injury or death.[2]
The combination is generally unsuitable for initial therapy when independent titration of the two components is required. Patients with significant renal impairment may also require a different regimen because thiazide effectiveness decreases as renal function declines.
What is the FDA regulatory status of fosinopril/hydrochlorothiazide?
The U.S. product is an approved small-molecule prescription drug. Its original regulatory pathway was a full NDA rather than an abbreviated generic application. Generic versions can enter through ANDAs demonstrating pharmaceutical equivalence and bioequivalence to the reference product.
| Regulatory issue |
Status |
| Active ingredient |
Fosinopril sodium plus hydrochlorothiazide |
| Dosage form |
Oral tablet |
| Therapeutic class |
ACE inhibitor/thiazide antihypertensive |
| U.S. reference product |
Monopril HCT |
| Original sponsor |
Bristol-Myers Squibb |
| U.S. application |
NDA 020149 |
| Regulatory pathway for generics |
ANDA |
| Biologic classification |
Not applicable |
| Biosimilar pathway |
Not applicable |
| Clinical development status |
Complete |
| Current innovation profile |
Mature generic combination |
FDA labeling describes the product as a fixed-dose combination for hypertension and identifies the pharmacologic and safety effects of both active ingredients.[1,2]
Are there active clinical trials for fosinopril/hydrochlorothiazide?
No active late-stage clinical development program is publicly identified for fosinopril sodium/hydrochlorothiazide. The combination was approved decades ago, and current research has largely shifted toward newer fixed-dose combinations, cardiovascular outcome trials, resistant-hypertension strategies, and newer approaches to chronic kidney disease and heart failure.
ClinicalTrials.gov contains historical studies involving fosinopril, hydrochlorothiazide, ACE inhibitors, or hypertension treatment, but those records do not indicate a current sponsor-led program designed to expand the commercial label for the specific fixed-dose combination.[3]
What did the original clinical evidence show?
The original development program evaluated blood-pressure reduction and tolerability in patients with hypertension. The clinical rationale was conventional: fosinopril addressed renin-angiotensin-system activity, while hydrochlorothiazide provided complementary natriuretic activity.
The combination's development value was primarily pharmacodynamic and commercial rather than based on a novel disease-modifying effect. It did not generate the type of large cardiovascular-outcomes evidence now commonly used to differentiate newer therapies.
Are new indications likely?
A new indication is unlikely without a commercial sponsor willing to fund contemporary trials. Potential areas such as chronic kidney disease, heart failure, or resistant hypertension are now dominated by therapies with stronger guideline positioning and more recent outcomes evidence. A new trial program would face a high opportunity cost against generic pricing.
When did fosinopril/hydrochlorothiazide lose market exclusivity?
Market exclusivity has expired. The active ingredients have been generic for many years, and the product does not have the exclusivity profile of a recently approved branded drug.
Fosinopril itself was developed and commercialized in the 1990s. The compound and related formulation protection have long passed their primary U.S. patent terms. The reference product therefore cannot rely on current compound exclusivity to prevent ANDA competition.
What patents protect fosinopril/hydrochlorothiazide?
The commercially relevant patent estate is substantially expired. Historical protection included patents covering fosinopril, its active metabolite relationships, pharmaceutical compositions, and antihypertensive use. Patent protection for the original fosinopril product was associated with Merck/Bristol-Myers Squibb development and commercialization activities.
A current commercial review should distinguish between:
- Expired compound patents covering fosinopril or fosinopril sodium.
- Expired formulation or combination patents.
- Any later patents covering manufacturing processes or specific solid forms.
- Patents listed in the FDA Orange Book for the reference product.
Current commercial barriers are regulatory and economic rather than a live blocking patent. The FDA Orange Book should be checked for the most recent listing status because patent listings can change through delisting, expiration, or product-status updates.[4]
| Protection category |
Current significance |
| Fosinopril compound protection |
Expired |
| Hydrochlorothiazide compound protection |
Expired |
| Original fixed-dose combination protection |
Expired or commercially ineffective |
| Formulation patents |
No known active barrier of material commercial significance |
| Method-of-use patents |
No known active barrier of material commercial significance |
| Manufacturing patents |
Potentially relevant to individual suppliers, but not a market-wide block |
| Regulatory exclusivity |
Expired |
What is the Orange Book status of Monopril HCT?
Monopril HCT is a legacy reference product. Its commercial significance is materially lower than during the branded period, and generic ANDA competition is the principal market structure.
The Orange Book provides the authoritative record for current approved products, therapeutic equivalence evaluations, patent listings, and exclusivity information.[4] For this product category, the key diligence question is not whether the historical brand had patents, but whether any unexpired, listed patent remains capable of delaying approval of a specific generic application.
No active exclusivity period is expected for fosinopril sodium/hydrochlorothiazide. No current pediatric, orphan, or new chemical entity exclusivity is associated with the mature product.
Which companies are challenging fosinopril/hydrochlorothiazide patents?
The product is no longer characterized by an active, high-value Paragraph IV challenge cycle. Generic competition has already entered the market through the ANDA pathway, making historical patent challenges less important to current valuation.
The likely generic supplier set has included companies active in legacy cardiovascular products, such as:
- Teva Pharmaceuticals
- Mylan, now part of Viatris
- Sandoz
- Watson/Actavis, now associated with Teva’s historical generic operations
- Various regional and contract manufacturers
Supplier participation can vary by dosage strength, manufacturing site, and current product availability. FDA approval does not guarantee continuous commercial supply. Generic manufacturers may discontinue low-volume strengths when pricing falls below economically viable levels.[5]
Are there current Paragraph IV litigation risks?
No material active Paragraph IV litigation risk is publicly associated with the mature fosinopril/hydrochlorothiazide product. Any historical ANDA disputes would have been resolved long before current commercial planning.
For a new entrant, the relevant risks are more likely to involve:
- Bioequivalence failure.
- Manufacturing-site deficiencies.
- Product discontinuation by incumbent suppliers.
- Low expected pricing.
- Limited wholesaler demand.
- State substitution and formulary dynamics.
What is the market size for fosinopril/hydrochlorothiazide?
The product-specific market is a small segment of the broader antihypertensive market. Public company reporting generally does not disclose revenue for this combination separately because generic sales are aggregated within broader cardiovascular portfolios.
The market is constrained by several factors:
| Market factor |
Effect on fosinopril/hydrochlorothiazide |
| Generic availability |
Reduces price and brand differentiation |
| Large number of alternative combinations |
Limits prescription growth |
| ACE-inhibitor cough and angioedema risk |
Encourages use of ARB-based alternatives |
| Inexpensive separate-component therapy |
Reduces the value of fixed-dose packaging |
| Mature clinical evidence |
Provides little basis for premium pricing |
| Low promotional activity |
Limits demand generation |
| Supply consolidation |
Creates occasional availability volatility |
Fosinopril has weaker current utilization than lisinopril and several ARBs. Hydrochlorothiazide remains widely used, but most demand is attached to other combinations, including lisinopril/hydrochlorothiazide, losartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, and olmesartan/hydrochlorothiazide.
What revenue exposure exists?
Revenue exposure is limited for the originator and potentially modest for generic manufacturers. The originator does not have a durable branded revenue stream comparable to an active-patent product. Generic revenue depends on volume, contract access, supply continuity, and the number of competing suppliers.
A new entrant should expect a low-price, low-margin market unless it obtains a supply advantage, a temporarily limited competitor field, or a channel-specific contract. Product-level global revenue estimates are not reliably disclosed in public filings.
How does fosinopril/hydrochlorothiazide compare with competing combinations?
| Product |
Primary strategic advantage |
Principal disadvantage |
| Fosinopril/HCTZ |
Established ACE inhibitor/thiazide combination; generic affordability |
Lower prescribing momentum and limited differentiation |
| Lisinopril/HCTZ |
Broad familiarity and large generic base |
ACE-inhibitor class adverse effects |
| Losartan/HCTZ |
ARB option with high physician familiarity |
Generic competition and class-level substitution |
| Valsartan/HCTZ |
Strong ARB positioning and multiple strengths |
Less price differentiation than older products |
| Amlodipine/benazepril |
Calcium-channel blocker plus ACE inhibitor |
Edema, cough, and more complex tolerability considerations |
| Olmesartan/HCTZ |
Effective fixed-dose ARB combination |
Higher historical brand and generic competition |
| Separate fosinopril plus HCTZ |
Flexible titration |
Lower adherence convenience than a fixed-dose tablet |
The strongest competitive disadvantage is clinical familiarity. Lisinopril and losartan have much larger prescribing bases, while ARB combinations are often preferred when ACE-inhibitor cough is a concern.
What generic launch scenarios exist?
A new generic launch would likely follow one of three scenarios.
Standard multi-source launch
Several suppliers remain active, resulting in low wholesale pricing and limited market share for each entrant. This is the most likely long-term scenario.
Temporary shortage or supplier exit
If one or more manufacturers discontinue a strength, a new entrant could obtain improved pricing or share. Such opportunities are difficult to forecast and may disappear after additional suppliers re-enter.
Contract-manufacturing or regional launch
A manufacturer may target selected markets, institutional buyers, or private-label channels rather than pursue broad retail distribution. This can reduce commercial overhead but also limits volume.
The absence of a blocking patent makes timing primarily dependent on FDA approval, manufacturing readiness, and customer contracting. Patent-based launch delays are not expected to be the principal issue.
How strong is the patent estate for fosinopril/hydrochlorothiazide?
The patent estate is weak from a current commercial-protection perspective.
| Strength criterion |
Assessment |
| Active compound patent |
No meaningful protection expected |
| Active combination patent |
No meaningful market-wide protection expected |
| Regulatory exclusivity |
None expected |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Limited or expired |
| Manufacturing know-how |
Potentially relevant at supplier level |
| Litigation leverage |
Low |
| Generic entry barrier |
Low |
Any remaining process or formulation patent would need to be evaluated claim by claim. Such patents are unlikely to restore branded pricing unless they cover a commercially essential product attribute and can be enforced against the relevant manufacturing route.
What is the projected market outlook through 2030?
The outlook is stable to declining in value terms.
| Period |
Expected market direction |
| 2025-2026 |
Stable generic demand with continued price pressure |
| 2027-2028 |
Gradual volume erosion as prescribing shifts to ARB combinations and other regimens |
| 2029-2030 |
Mature residual market; revenue declines likely exceed unit declines |
Unit demand may persist because hypertension treatment is chronic and the ingredients remain inexpensive. Value growth is unlikely. A reasonable strategic assumption is low-single-digit annual revenue decline over the medium term, subject to supply disruptions and regional reimbursement changes. This is a market-direction estimate, not a reported product-specific consensus forecast.
The largest upside scenario is a supply shortage among incumbent manufacturers. The largest downside scenario is further substitution toward ARB/thiazide combinations or discontinuation of low-volume strengths.
Key Takeaways
- Fosinopril sodium/hydrochlorothiazide is a mature fixed-dose antihypertensive combination.
- The U.S. reference product is Monopril HCT, historically sponsored by Bristol-Myers Squibb.
- Clinical development is complete, and no meaningful active trial program is publicly identified.
- Patent and regulatory exclusivity have expired.
- No material active Paragraph IV or biosimilar risk is expected.
- The market is generic, fragmented, and price sensitive.
- Lisinopril/HCTZ and ARB/thiazide combinations are the principal competitive alternatives.
- Product-specific revenue is not generally disclosed by public companies.
- The market outlook through 2030 is stable to declining, with occasional supply-driven opportunities.
- Manufacturing reliability, FDA compliance, and channel access matter more than patent protection.
FAQs
Is fosinopril/hydrochlorothiazide still available?
Availability depends on country, dosage strength, and manufacturer. The product is a legacy generic combination and may have intermittent supply differences across pharmacies and wholesalers.
Is fosinopril/hydrochlorothiazide interchangeable with lisinopril/hydrochlorothiazide?
No. The products contain different ACE inhibitors and are not automatically interchangeable on a milligram-for-milligram basis. Prescribers must select the replacement regimen and dose.
Does fosinopril/hydrochlorothiazide have biosimilar competition?
No. Biosimilars apply to biological products. Fosinopril and hydrochlorothiazide are small-molecule drugs competing through generic approval pathways.
Can a generic manufacturer obtain exclusivity for this product?
A generic manufacturer could receive limited approval-related exclusivity in specific circumstances, such as a first-filer Paragraph IV position. No current commercially significant exclusivity period is expected for this mature product.
Does hydrochlorothiazide improve the commercial value of fosinopril?
It improves dosing convenience and provides complementary blood-pressure control, but it does not create meaningful current patent value. The combination remains exposed to generic substitution and competition from more widely used fixed-dose products.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- DailyMed. (n.d.). Fosinopril sodium and hydrochlorothiazide tablet prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
- ClinicalTrials.gov. (n.d.). Search results for fosinopril hydrochlorothiazide. U.S. National Library of Medicine. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
- U.S. Food and Drug Administration. (n.d.). FDA-approved drug products and generic drug availability resources. https://www.fda.gov/drugs/generic-drugs/approved-drug-products-and-generic-drug-availability-resources
